Share This Page
Suppliers and packagers for generic pharmaceutical drug: ENSARTINIB HYDROCHLORIDE
✉ Email this page to a colleague
ENSARTINIB HYDROCHLORIDE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Xcovery | ENSACOVE | ensartinib hydrochloride | CAPSULE;ORAL | 218171 | NDA | Xcovery Holdings, Inc. | 83076-1025-3 | 30 CAPSULE in 1 BOTTLE (83076-1025-3) | 2025-04-30 |
| Xcovery | ENSACOVE | ensartinib hydrochloride | CAPSULE;ORAL | 218171 | NDA | Xcovery Holdings, Inc. | 83076-1100-6 | 60 CAPSULE in 1 BOTTLE (83076-1100-6) | 2025-04-30 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: ENSARTINIB HYDROCHLORIDE
Introduction
Ensartinib hydrochloride is an investigational ALK (anaplastic lymphoma kinase) inhibitor primarily developed for treating ALK-positive non-small cell lung cancer (NSCLC). As a targeted therapy, ensuring reliable sourcing of high-quality ensartinib hydrochloride is critical for pharmaceutical companies, research institutions, and contract manufacturing organizations (CMOs). This article explores the key suppliers involved in producing ensartinib hydrochloride, their manufacturing capacities, certifications, and strategic considerations for sourcing this compound efficiently and compliantly.
Understanding Ensartinib Hydrochloride: A Brief Overview
Ensartinib, marketed under the developmental code X-396, is a potent, selective ALK inhibitor designed to overcome resistance associated with other ALK inhibitors like crizotinib. Its hydrochloride salt form enhances stability and solubility, making it suitable for pharmaceutical formulation. Currently, ensartinib remains in clinical stages or under regulatory review, requiring sourcing of GMP-grade material for clinical trials and potential commercialization.
Key Attributes for Ensartinib Hydrochloride Suppliers
Qualities sought in suppliers include:
- GMP Compliance: Ensuring production under Good Manufacturing Practices.
- High Purity (> 99%): Critical for clinical safety and efficacy.
- Certifications: FDA, EMA, ISO, and other relevant approvals.
- Reliable Supply Chain: Capacity to meet demand fluctuations.
- Transparency & Traceability: Comprehensive documentation for regulatory audits.
- Competitive Pricing: Balancing quality with affordability.
主要供应商分析
1. Shanghai ChemPartner
Overview: Shanghai ChemPartner, based in China, is a prominent CRO and CMO offering custom synthesis, including complex APIs like ensartinib hydrochloride. They possess advanced synthesis capabilities, extensive quality management systems, and a proven track record in providing high-purity compounds for clinical trials.
Strengths:
- GMP-certified manufacturing facilities.
- Proven expertise in kinase inhibitors and targeted therapies.
- Capacity for large-scale production.
- Experience working with global pharmaceutical companies.
Considerations: Their geographical location facilitates competitive pricing but may pose logistical considerations for discharge to North America and Europe.
2. WuXi AppTec
Overview: WuXi AppTec is a leading global CRO and CDMO with a broad portfolio, including custom synthesis of niche APIs like ensartinib hydrochloride. Their integrated services streamline the transition from development to manufacturing.
Strengths:
- Global infrastructure with facilities in China, the U.S., and Europe.
- GMP-certified, ISO-compliant production.
- Extensive quality assurance processes.
- Strong regulatory support.
Considerations: As a large-scale provider, WuXi's capacity and pricing are competitive, though demand for complex APIs can influence lead times.
3. Sierra Oncology (through partnerships)
Overview: Sierra Oncology employs strategic collaborations to access specialized kinase inhibitors, including ensartinib derivatives. They focus on high-quality synthesis for clinical and commercial use.
Strengths:
- Proven expertise in ALK inhibitors.
- Capable of producing GMP-grade compounds.
- Established supply chain for clinical trial materials.
Considerations: Typically, engagement occurs through partnerships, which could add layers of negotiations and lead time.
4. Localized API Manufacturers in India
India hosts several API manufacturers capable of synthesizing ensartinib hydrochloride, often offering cost advantages:
- Neuland Laboratories: Experienced in complex APIs with GMP certifications.
- Granules India: Focused on high-volume API production.
- Shilpa Medicare: Known for specialty APIs and contract manufacturing.
Strengths:
- Cost-effective manufacturing.
- Growing capacity for complex APIs.
- Access to robust supply chains.
Considerations:
- Ensuring strict GMP compliance and regulatory standards.
- Potential variability in quality and documentation.
5. Contract Research & Manufacturing Organizations (CROs & CMOs)
Other noted providers include Aziyo Biologics, Jubilant Biosys, and Cambrex, which can manufacture small or pilot-scale batches of ensartinib hydrochloride, primarily for clinical trial material.
Strategic Sourcing Considerations
- Regulatory Compliance: Verify supplier GMP certifications, batch documentation, and regulatory history.
- Supply Chain Reliability: Evaluate their capacity and lead times, especially given the complex synthesis involved.
- Intellectual Property (IP): Clarify licensing and confidentiality agreements, considering ensartinib is still under clinical development.
- Cost and Lead Time: Balance between regional proximity, manufacturing capacity, and price.
- Quality Control: Prioritize suppliers with proven QC processes, stability testing, and analytical validation.
Emerging Trends and Opportunities
- Local Manufacturing Initiatives: Governments incentivize domestic production, potentially reducing lead times and costs.
- Advanced Synthesis Techniques: Innovation in process chemistry can streamline production, improving yields and purity.
- Strategic Partnerships: Collaborations with established API manufacturers facilitate technology transfer and risk mitigation.
Conclusion
Sourcing ensartinib hydrochloride hinges on identifying suppliers with robust GMP compliance, proven synthesis capabilities, and reliable supply chains. Global players such as WuXi AppTec and Shanghai ChemPartner dominate the landscape, providing high-quality, scalable options for clinical and commercial needs. Indian API manufacturers offer cost-effective alternatives, provided regulatory and quality standards are met. Strategic evaluation of each supplier’s capabilities, certifications, and logistical considerations ensures continuity, regulatory compliance, and cost-efficiency in sourcing this crucial targeted therapy.
Key Takeaways
- Ensartinib hydrochloride is primarily supplied by Chinese CROs and CMOs such as WuXi AppTec and Shanghai ChemPartner, known for GMP compliance and high purity.
- Indian API manufacturers present cost-efficient options with increasing capabilities in complex API synthesis, contingent upon quality assurance.
- Regulatory certifications, supply chain reliability, and manufacturing capacity are essential criteria for selecting suppliers.
- Technological advances and local manufacturing trends could influence future supply dynamics.
- Strategic partnerships and thorough due diligence mitigate risks associated with sourcing an investigational drug like ensartinib hydrochloride.
FAQs
1. What are the primary regions for sourcing ensartinib hydrochloride?
Primarily from China through companies like WuXi AppTec and Shanghai ChemPartner, with emerging options in India. Western suppliers are limited due to the drug's investigational status and complex synthesis.
2. What regulatory considerations are involved in sourcing this API?
Ensure suppliers hold GMP certifications compliant with regulatory authorities like the FDA and EMA, with comprehensive documentation for regulatory submission and quality assurance.
3. Can I procure ensartinib hydrochloride for commercial use now?
Currently, ensartinib remains in clinical development stages, so commercial-scale procurement is limited. However, GMP-grade supplies are essential for clinical trials.
4. What are the main challenges in sourcing ENSARTINIB HYDROCHLORIDE?
Complex synthesis, maintaining high purity, regulatory compliance, and ensuring reliable supply chain continuity are key challenges.
5. Are there alternatives to ensartinib hydrochloride for ALK-positive NSCLC?
Yes, other ALK inhibitors like crizotinib, alectinib, brigatinib, and lorlatinib are commercially available. Ensartinib aims to overcome resistance and improve efficacy profiles.
References:
[1] Pharmaceutical databases and supplier websites (e.g., WuXi AppTec, Shanghai ChemPartner).
[2] Clinical trial disclosures and drug development reports (e.g., ClinicalTrials.gov).
More… ↓
